Author Search Results :: UTM Library Massive Scholar Tracking

1

$Role of Bispecific Antibodies in Relapsed/Refractory Diffuse Large B-Cell Lymphoma in the CART Era$

Role of Bispecific Antibodies in Relapsed/Refractory Diffuse Large B-Cell Lymphoma in the CART Era by Eva González Barca

Published 2022-07-01

Get full text

Article

2

Low-Dose PET/CT and Full-Dose Contrast-Enhanced CT at the Initial Staging of Localized Diffuse Large B-Cell Lymphomas by Aida Sabaté-Llobera, Montserrat Cortés-Romera, Santiago Mercadal, Javier Hernández-Gañán, Helena Pomares, Eva González-Barca, Cristina Gámez-Cenzano

Published 2016-01-01

Get full text

Article

3

Impact of interleukin-10 polymorphisms (−1082 and −3575) on the survival of patients with lymphoid neoplasms by Eva Domingo-Domènech, Yolanda Benavente, Eva González-Barca, Carlos Montalban, Josep Gumà, Ramón Bosch, Sophia S. Wang, Qing Lan, Denise Whitby, Alberto Fernández de Sevilla, Nathaniel Rothman, Sílvia de Sanjosé

Published 2007-11-01

Get full text

Article

4

$Pan-phosphatidylinositol 3-kinase inhibition with buparlisib in patients with relapsed or refractory non-Hodgkin lymphoma$

Pan-phosphatidylinositol 3-kinase inhibition with buparlisib in patients with relapsed or refractory non-Hodgkin lymphoma by Anas Younes, Gilles Salles, Giovanni Martinelli, Robert Gregory Bociek, Dolores Caballero Barrigon, Eva González Barca, Mehmet Turgut, John Gerecitano, Oliver Kong, Chaitali Babanrao Pisal, Ranjana Tavorath, Won Seog Kim

Published 2017-12-01

Get full text

Article

5

Prospective phase II trial of extended treatment with rituximab in patients with B-cell post-transplant lymphoproliferative disease by Eva González-Barca, Eva Domingo-Domenech, Francisco Javier Capote, Jose Gómez-Codina, Antonio Salar, Alicia Bailen, Jose-María Ribera, Andres López, Javier Briones, Andres Muñoz, Maite Encuentra, Alberto Fernández de Sevilla

Published 2007-11-01

Get full text

Article

6

PB2304: FIVE-YEAR SUBGROUP ANALYSIS OF TAFASITAMAB + LENALIDOMIDE FROM THE PHASE II L-MIND STUDY IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA by Johannes Duell, Pau Abrisqueta, Martin Dreyling, Gianluca Gaidano, Eva González Barca, Wojciech Jurczak, Anna Marina Liberati, Kami Maddocks, Tobias Menne, Zsolt Nagy, Olivier Tournilhac, Abhishek Bakuli, Aasim Amin, Konstantin Gurbanov, Gilles Salles

Published 2023-08-01

Get full text

Article

7

P1138: FIVE-YEAR EFFICACY AND SAFETY OF TAFASITAMAB IN PATIENTS WITH RELAPSED OR REFRACTORY DLBCL: FINAL RESULTS FROM THE PHASE II L-MIND STUDY by Johannes Duell, Pau Abrisqueta, Marc Andre, Marinela Augustin, Gianluca Gaidano, Eva González Barca, Wojciech Jurczak, Nagesh Kalakonda, Anna Marina Liberati, Kami Maddocks, Tobias Menne, Zsolt Nagy, Olivier Tournilhac, Abhishek Bakuli, Aasim Amin, Konstantin Gurbanov, Gilles Salles

Published 2023-08-01

Get full text

Article

8

$Autologous stem cell transplantation after conditioning with yttrium-90 ibritumomab tiuxetan BEAM in refractory non-Hodgkin diffuse large B-cell lymphoma: results of a prospective, multicenter, phase II clinical trial$

Autologous stem cell transplantation after conditioning with yttrium-90 ibritumomab tiuxetan BEAM in refractory non-Hodgkin diffuse large B-cell lymphoma: results of a prospective,... by Javier Briones, Silvana Novelli, José A. García-Marco, José F. Tomás, Teresa Bernal, Carlos Grande, Miguel A. Canales, Antonio Torres, José M. Moraleda, Carlos Panizo, Isidro Jarque, Francisca Palmero, Miguel Hernández, Eva González-Barca, Dulce López, Dolores Caballero

Published 2014-07-01

Get full text

Article

9

$Autologous stem cell transplantation after conditioning with yttrium-90 ibritumomab tiuxetan plus BEAM in refractory non-Hodgkin diffuse large B-cell lymphoma: results of a prospective, multicenter, phase II clinical trial$

Autologous stem cell transplantation after conditioning with yttrium-90 ibritumomab tiuxetan plus BEAM in refractory non-Hodgkin diffuse large B-cell lymphoma: results of a prospec... by Javier Briones, Silvana Novelli, José A. García-Marco, José F. Tomás, Teresa Bernal, Carlos Grande, Miguel A. Canales, Antonio Torres, José M. Moraleda, Carlos Panizo, Isidro Jarque, Francisca Palmero, Miguel Hernández, Eva González-Barca, Dulce López, Dolores Caballero

Published 2014-03-01

Get full text

Article

10

Total metabolic tumor volume as a survival predictor for patients with diffuse large B-cell lymphoma in the GOYA study by Lale Kostakoglu, Federico Mattiello, Maurizio Martelli, Laurie H. Sehn, David Belada, Chiara Ghiggi, Neil Chua, Eva González-Barca, Xiaonan Hong, Antonio Pinto, Yuankai Shi, Yoichi Tatsumi, Christopher Bolen, Andrea Knapp, Gila Sellam, Tina Nielsen, Deniz Sahin, Umberto Vitolo, Marek Trněný

Published 2021-08-01

Get full text

Article

11

$European phase II study of mogamulizumab, an anti-CCR4 monoclonal antibody, in relapsed/refractory peripheral T-cell lymphoma$

European phase II study of mogamulizumab, an anti-CCR4 monoclonal antibody, in relapsed/refractory peripheral T-cell lymphoma by Pier Luigi Zinzani, Lionel Karlin, John Radford, Dolores Caballero, Paul Fields, Martine E. D. Chamuleau, Francesco d’Amore, Corinne Haioun, Catherine Thieblemont, Eva González-Barca, Carlos Grande García, Peter W. Johnson, Gustaaf W. van Imhoff, Thomas Ng, Karen Dwyer, Franck Morschhauser

Published 2016-10-01

Get full text

Article

12

Rituximab maintenance after bendamustine-based treatment for follicular lymphoma and mantle cell lymphoma may exert a negative influence on SARS-CoV-2 infection outcomes by Ángel Serna, Víctor Navarro, Gloria Iacoboni, Laia López, Juan-Manuel Sancho, Eva González-Barca, Alberto López-García, Raúl Córdoba, Adolfo Sáez, Ana Jiménez Ubieto, Ainara Ferrero, Tomás García, Ángela Sánchez, Cristina García, Marc Bosch, Alba Cabirta, Moraima Jiménez, Ana Marín-Niebla, Francesc Bosch, Pau Abrisqueta

Published 2024-07-01

Get full text

Article

13

$Long-term outcomes from the phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma$

Long-term outcomes from the phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma by Johannes Duell, Kami J. Maddocks, Eva González-Barca, Wojciech Jurczak, Anna Marina Liberati, Sven de Vos, Zsolt Nagy, Aleš Obr, Gianluca Gaidano, Pau Abrisqueta, Nagesh Kalakonda, Marc André, Martin Dreyling, Tobias Menne, Olivier Tournilhac, Marinela Augustin, Andreas Rosenwald, Maren Dirnberger-Hertweck, Johannes Weirather, Sumeet Ambarkhane, Gilles Salles

Published 2021-08-01

Get full text

Article

14

$R-ESHAP as salvage therapy for patients with relapsed or refractory diffuse large B-cell lymphoma: the influence of prior exposure to rituximab on outcome. A GEL/TAMO study$

R-ESHAP as salvage therapy for patients with relapsed or refractory diffuse large B-cell lymphoma: the influence of prior exposure to rituximab on outcome. A GEL/TAMO study by Alejandro Martín, Eulogio Conde, Montserrat Arnan, Miguel A. Canales, Guillermo Deben, Juan M. Sancho, Rafael Andreu, Antonio Salar, Pedro García-Sanchez, Lourdes Vázquez, Sara Nistal, María-José Requena, Eva M. Donato, José A. González, Ángel León, Concepción Ruiz, Carlos Grande, Eva González-Barca, María-Dolores Caballero

Published 2008-12-01

Get full text

Article

15

MYC protein expression and genetic alterations have prognostic impact in patients with diffuse large B-cell lymphoma treated with immunochemotherapy by Alexandra Valera, Armando López-Guillermo, Teresa Cardesa-Salzmann, Fina Climent, Eva González-Barca, Santiago Mercadal, Íñigo Espinosa, Silvana Novelli, Javier Briones, José L. Mate, Olga Salamero, Juan M. Sancho, Leonor Arenillas, Sergi Serrano, Nadina Erill, Daniel Martínez, Paola Castillo, Jordina Rovira, Antonio Martínez, Elias Campo, Luis Colomo

Published 2013-10-01

Get full text

Article

16

$Long-term outcomes from the Phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma$